Adjuvant treatment of postmenopausal women w/ hormone receptor +ve early invasive breast cancer. Advanced breast cancer in postmenopausal women w/ hormone receptor +ve or hormone receptor unknown locally advanced or metastatic breast cancer.
Biochemically define menopause in any patient where there is doubt about menopausal status. Formally assess bone mineral density by bone densitometry (eg, DEXA scanning) in women w/ or at risk of osteoporosis at the commencement of treatment & at regular intervals thereafter; carefully monitor & initiate appropriate treatment or prophylaxis for osteoporosis. Not to be used outside clinical trials w/ LHRH analogues. May reduce bone mineral density w/ a possible consequent increased risk of fracture; consider use of bisphosphonates in postmenopausal women. Possible asthenia & somnolence; observe caution when driving or operating machinery. Not recommended for use in childn.
Sign Out
